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Conclusions: Our study provided probabilities of lossFU and death in 
HIV patients. ARTs and health coverage were preventive-factors whereas 
males, old-age, OI, and shopping-around hospital were risk factors of loss-
FU and death.
 
P3.1.189
New insights on therapy choices in non-small 
cell lung cancer using a flexible extension of the 
standard Cox’s model
W Wynant1, M Abrahamowicz1, I Gioulbasanis2, G Kasymjanova3, 
JS Agulnik3, B Gagnon4
1McGill University, Montreal, Canada, 2University Hospital of Larissa, 
Larissa, Greece, 3Jewish General Hospital, Montreal, Canada, 4Laval 
University, Quebec, Canada
 
Non-small cell lung (NSCL) cancer accounts for about 80% of all cases of 
lung cancer. Most of the patients present with advanced-stage disease at 
diag nosis and have a poor prognosis. Moreover, chemotherapy confers a 
mod est survival improvement, compared with supportive care alone. 
Therefore, probability of survival conditional on patient characteristics is 
a meaningful metric for prognosis and therapy choices. In NSCL cancer, 
this could guide treatment by recognizing pa tients at high risk for poor 
survival who might be considered to earlier intervention and could help 
for optimal clinical management. 
We estimated survival probabilities from data on 269 patients with NSCL 
cancer. As misspecification of covariates’ effects can have a huge impact, 
we extended the standard Cox´s model to allow (i) non-linear effects of 
the covariates on the logarithm of the hazard and (ii) covariates effects to 
change over time. We also considered a flexible modeling of the baseline 
hazard to avoid step functions, biologically implausible. 
Our results emphasize the importance of taking into account the potential 
time-dependent and non-linear effects of biomarkers and new insights 
obtained from survival curves. For example, our survival probability es-
timate at 6 months after chemotherapy, for patients who smoke, had a 
double-agent chemotherapy but with low blood levels of albumin and 
C-reactive protein and average level of various other biomarkers (includ-
ing neutrophil counts and alkaline phosphatise) was only 40%, whereas 
the estimate from the widespread standard Cox´s model was 85%. 
This highlights a profile of patients who may be targeted to earlier inter-
vention.
 
P3.1.191
Heterogeneous M/M/1 type queuing models
S Yiu1
1MRC Biostatistics Unit, Cambridge, United Kingdom
 
Motivated by the need to account for unobserved heterogeneity from a 
missing important covariate in a longitudinal reversible count data set-
ting, this work presents three M/M/1 type queuing models with random 
effects. 
The standard M/M/1 queuing model is considered with and without an 
absorbing state, followed by the M/M/1 queuing model with one modified 
transition intensity. By convenient choice of mixing distributions, closed 
form expressions for the marginal likelihoods are available, thereby pro-
viding tractability. 
The methodology is illustrated with an application to a psoriatic arthritis 
data set where modelling the number of active joints is of interest. 
 
P3.2 Diagnostic studies
P3.2.91
Sample size calculations for confidence limits 
of prevalence of disease adjusted for estimated 
sensitivity and specificity
Z Lang1, J Reiczigel1
1Szent István University, Faculty of Veterinary Science, Budapest, 
Hungary
Prevalence of a disease or other characteristic of a target population is 
frequently estimated by diagnostic tests. Lang and Reiczigel (2014) con-
structed approximate confidence intervals for prevalence when apparent 
prevalence, sensitivity and specificity were estimated from independent 
binomial samples. When the sample sizes are small, the confidence inter-
vals obtained may prove to be too wide to cope with a required precision. 
The solution for this problem is to calculate suitable sample sizes based on 
preliminary diagnostic parameter estimates stemming from earlier studies 
or estimated from the actual data and draw new samples from both the 
target population and the populations to re-estimate sensitivity, specific-
ity and prevalence. In this presentation we provide sample size formulas 
e.g. when the planned length of the confidence interval of prevalence is 
prescribed and the estimated values of the diagnostic parameters remain 
unchanged. 
When the variances of the estimates of sensitivity or specificity are poor it 
is advisable to re-estimate them from larger new independent samples. If 
prevalence is small then the variance of specificity has to be reduced first 
of all. 
Analogously, when prevalence is close to 1 the variance of sensitivity is 
advised to be controlled.
P3.2.95
Systematic review and meta-analysis of 
diagnostic accuracy of FDG-PET in dementia and 
Alzheimer’s disease
YE Lee1, JE Choi1, J-Y Kim1, YH Yoo2, DY Lee3, S-H Park1, S-K Son1, 
Y-K Lee1, E Shin1, CH Ryu2, C-H Sohn3, J-Y Lee4, Y Kim4
1National Evidence-based Healthcare Collaborating Agency, Seoul, 
Republic of Korea, 2Department of Nuclear Medicine, Gangnam 
Severance Hospital, Seoul, Republic of Korea, 3Seoul National 
University Hospital, Seoul, Republic of Korea, 4SMG-SNU Boramae 
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As aging population is rapidly increasing, it is estimated that prevalence of 
dementia among older adults would be doubled every twenty years and 
number of patients would increase by one million until 2027. Dementia 
would lead to a burden of care on family members, care-givers, and even 
societies due to social and economic cost. Therefore, early diagnosis of 
dementia is important step to prevent further worsening of disease and 
improve quality of life of dementia patients and their family. In this study, 
we assessed diagnostic accuracy of FDG-PET in evaluation of dementia, 
which known as a tool for detecting reduced glucose metabolism in pa-
tient’s brain even before the development of dementia symptoms. 
To evaluate diagnostic accuracy in early detection of dementia and 
Alzheimer’s disease, we conducted systematic reviews of published arti-
cles, and identified 9 cross-sectional studies and 13 delayed cross-section-
al studies. Bivariate Meta-analysis of 9 cross-sectional studies resulted in a 
pooled sensitivity(SN) of 0.61(95% CI: 0.42-0.79), a pooled specificity(SP) of 
0.81(95% CI: 0.55-1.07). In 13 delayed cross-section studies, it resulted in a 
pooled SN of 0.81(95% CI: 0.72-0.91), and a pooled SP of 0.78(95% CI: 0.65-
0.92). With subgroup analyses in amnestic mild cognitive impairment(MCI) 
patients, the result suggested a pooled SN of 0.92(95% CI: 0.75-1.00), a 
pooled SP of 0.88(95% CI: 0.77-0.98). These results indicate that FDG-PET 
among amnestic MCI patients was most accurate in the aspects of pooled 
SN and SP in delayed cross-sectional studies.
